Latest Innovation News

Firebrick Pharma reports a $1.94 million cash reserve after a $1.4 million placement, supporting expanded Nasodine sales across Southeast Asia and the US. Board changes and increased operational costs mark a pivotal quarter for the pharmaceutical innovator.

Cochlear Limited reports steady FY25 financials alongside the launch of its innovative Nucleus Nexa cochlear implant system, setting the stage for projected double-digit profit growth in FY26.

Control Bionics has successfully raised $0.6 million through a shortfall placement, reinforcing investor confidence as it accelerates commercialisation of its neurotechnology in assistive communication and emerging sports markets.

Red Mountain Mining reports exceptional high-grade antimony and gold results from its Armidale Project in NSW, positioning itself strongly amid growing government support for critical minerals.

Acumentis Group Limited reported a robust FY25 with a 35% jump in operating profit, driven by strategic diversification and operational efficiency. The company is optimistic about FY26, anticipating economic improvements and new growth avenues.

Motio Limited has reported a robust Q1FY26 cash EBITDA exceeding $700,000, surpassing earlier guidance and marking over 20% growth year-on-year. The company also appointed industry veteran Justin Kingston as its new COO to spearhead commercial and operational expansion.

Michael Hill International reported steady FY25 financials amid challenging markets, with early FY26 trading showing promising margin improvements and mixed sales across regions.

Michael Hill International reported flat earnings in FY25 amid inflation and subdued demand, while new CEO Jonathan Waecker outlines a strategy focused on innovation, AI integration, and margin recovery heading into FY26.

Starpharma has secured a $5.5 million upfront payment from Genentech as part of a new collaboration to develop dendrimer-drug conjugates targeting cancer therapies. The partnership includes potential milestone payments exceeding half a billion dollars and tiered royalties.

MedAdvisor Solutions reported a steep 52.8% revenue decline in Q1 FY26, impacted by US regulatory pressures and vaccine program delays, while embarking on a strategic transformation to restore growth.

MedAdvisor reports a sharp 53% drop in 1Q FY26 revenue driven by U.S. regulatory and sector challenges, while advancing a major platform transformation and selling its ANZ business to emerge debt-free.

Vitasora Health has received $2.43 million from a cornerstone investor, advancing its $11 million capital raise and reinforcing its path to profitability by Q4 FY2026. The company’s expanding US partnerships and technology investments signal growing market confidence.